Cite
HARVARD Citation
Dimopoulos, M. et al. (2023). Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis. American journal of hematology. 98 (1), pp. E15-E19. [Online].